C. Conrad - Concepedia

Author

C. Conrad

Also Known As

C C Conrad, C Conrad, C K Conrad, C. Conrad, C. K. Conrad, C.K. Conrad, Carol Conrad, Carol K. Conrad, Davis, Stephanie D., R. Merrell

144

Publications

5.8K

Citations

H-Index

126

Concepts

All Affiliations

Stanford University Johns Hopkins University Boston Children's Hospital Baylor College of Medicine Washington University in St. Louis

About

C. Conrad is an author at Stanford University specializing in medicine, pharmacology, and neuro-oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	27	34	3.5K
2	Health Sciences	7	7	511
3	Natural Sciences	1	1	54
4	Public Health	1	1	215
5	Social Sciences	1	1	37

C. Conrad

Publications

5.5K

Citations

H-Index

Page 1

	Year	Citations
Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector. Terence R. Flotte, Sandra Afione, C. Conrad, Proceedings of the National Academy of Sciences Adeno-associated Virus VectorViral PathogenesisImmunologyPathologyViral Structural Protein	1993	487
A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo Arifumi Iwamaru, Sławomir Szymański, Eiji Iwado, Oncogene Neuro-oncologyNovel InhibitorMedicineMalignant Glioma CellsApoptosis	2006	368
A Phase I Study of an Adeno-Associated Virus-CFTR Gene Vector in Adult CF Patients with Mild Lung Disease. Johns Hopkins Children's Center, Baltimore, Maryland Terence R. Flotte, Barrie Carter, C. Conrad, Human Gene Therapy Advanced Lung DiseaseLung InflammationRespiratory DiseasesJohns Hopkins ChildrenPulmonary Alveolar Proteinosis	1996	273
Regulation of gastric emptying in humans by cholecystokinin. Rodger A. Liddle, Eugene Morita, C. Conrad, Journal of Clinical Investigation NutritionBody CompositionGastrointestinal PharmacologyPhysiologyClinical Nutrition	1986	271
A Phase II, Double-Blind, Randomized, Placebo-Controlled Clinical Trial of tgAAVCF Using Maxillary Sinus Delivery in Patients with Cystic Fibrosis with Antrostomies John A. Wagner, Ilynn B. Nepomuceno, Anna H. Messner, Human Gene Therapy Clinical ImmunologyTranslational MedicineAutoimmune DiseaseImmunologySinus Histopathology	2002	265
High-dose oral <i>N</i> -acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis Rabindra Tirouvanziam, C. Conrad, Teodoro Bottiglieri, Proceedings of the National Academy of Sciences	2006	252
Phase I Trial of Intranasal and Endobronchial Administration of a Recombinant Adeno-Associated Virus Serotype 2 (rAAV2)-CFTR Vector in Adult Cystic Fibrosis Patients: A Two-Part Clinical Study Terence R. Flotte, Pamela L. Zeitlin, Thomas C. Reynolds, Human Gene Therapy	2003	243
In vivo model of adeno-associated virus vector persistence and rescue Sandra Afione, C. Conrad, W.G. Kearns, Journal of Virology In Vivo Gene TherapyImmunologyViral PathogenesisViral DynamicViral Persistence	1996	224
Proteins but not amino acids, carbohydrates, or fats stimulate cholecystokinin secretion in the rat R.A. Liddle, G. M. Green, C. Conrad, American Journal of Physiology-Gastrointestinal and Liver Physiology NutritionAmino AcidsImmunologyGastroenterologyGastrointestinal Peptide Hormone	1986	215
Safety and Biological Efficacy of an Adeno‐Associated Virus Vector–Cystic Fibrosis Transmembrane Regulator (AAV‐CFTR) in the Cystic Fibrosis Maxillary Sinus John A. Wagner, Anna H. Messner, Mary Lynn Moran, The Laryngoscope	1999	209

Page 1